-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-23
A 2026 FASEB Journal study developed chemically modified p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, suppressed tumor growth in an orthotopic mouse model, and limited systemic exposure, while also identifying translational questions about dosing, formulation, durability, and safety.
-
Mifepristone (RU486) as a Receptor-Context Probe
2026-08-22
Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a reversible perturbation tool for testing receptor-dependent biology across reproductive and cancer models. This guide connects its product-defined mechanisms with receptor heterogeneity, assay design, and interpretation of translational evidence.
-
3-Deazaadenosine hydrochloride in m6A Workflows
2026-08-22
Use 3-Deazaadenosine hydrochloride as a pathway-level probe to test whether SAHH-dependent methyl metabolism contributes to IGF2BP1–TUBB4B signaling in hepatic stellate cells. This workflow combines chemical perturbation with RNA stability, proliferation, migration, and fibrosis-marker assays to distinguish upstream methylation effects from direct target inhibition.
-
Protease Inhibitor Cocktail for Migrasome Studies
2026-08-21
Discover how Protease Inhibitor Cocktail EDTA-Free supports reliable CYR61, ERK, co-IP, and migrasome-related assays by controlling proteolysis without chelating divalent cations. This practical guide translates recent irradiation-BMSC research into better sample-handling decisions.
-
5-HT3 Antagonists and Renal OCT2/MATE1 Transport
2026-08-20
George and colleagues systematically compared five 5-HT3 antagonists in human OCT2 and MATE1 cell models, identifying compound-specific inhibition of organic cation uptake and transepithelial secretion. The findings provide a mechanistic basis for investigating renal transporter-mediated drug interactions, while also highlighting why in vitro potency should not be equated directly with clinical risk.
-
Protease Inhibitor Cocktail: MS-SAFE Protocol
2026-08-20
This Protease Inhibitor Cocktail helps limit endogenous proteolysis during cell and tissue extraction while avoiding AEBSF, which can complicate mass spectrometry workflows. It is appropriate for broad protease inhibition in proteomic and biochemical sample preparation, but it does not replace separately validated metalloproteinase or phosphatase inhibition.
-
Topotecan HCl: Assay Workflows & Optimization
2026-08-19
Topotecan HCl supports mechanistic studies of topoisomerase I inhibition, schedule-dependent cytotoxicity, and tumor-model response. This workflow pairs concentration and exposure-time optimization with separate measurements of growth inhibition and cell killing for more interpretable lung, breast, and prostate cancer data.
-
Reactive Oxygen Species Assay Kit: Causal Design
2026-08-19
Learn how a Reactive Oxygen Species Assay Kit can distinguish superoxide-associated phenotypes from broader oxidative-stress claims. This guide uses DON immunotoxicity research to develop a more rigorous assay-design and interpretation framework.
-
2X HyperFusion High-Fidelity Master Mix for PCR
2026-08-18
The 2X HyperFusion High-Fidelity Master Mix is a ready-to-use reagent for high accuracy DNA amplification, cloning PCR applications, and selected CRISPR workflows. Its HyperFusion high-fidelity DNA polymerase combines processivity with 3′→5′ proofreading and is reported to generate blunt-ended products with lower error rates than Taq and Pfu polymerases.
-
Anti Reverse Cap Analog for Synthetic mRNA
2026-08-18
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, enables orientation-specific 5′ capping for higher-performing synthetic mRNA workflows. Its strongest use cases include transient transcription-factor delivery, cell reprogramming, gene-editing research, and assays where translation output must be separated from delivery or cell-state effects.
-
Anti Reverse Cap Analog for High-Yield mRNA
2026-08-17
Anti Reverse Cap Analog improves synthetic mRNA performance by enforcing productive cap orientation during in vitro transcription. This guide connects cap selection with reproducible expression assays, metabolic studies, and troubleshooting for mRNA therapeutics research.
-
Deferoxamine Mesylate in Ferroptosis Assays
2026-08-17
Deferoxamine mesylate is more than an iron-chelating agent: it is a practical tool for separating iron dependence, oxidative stress, and hypoxia signaling in cell assays. This guide translates ferroptosis research into better controls, exposure designs, and interpretation strategies.
-
Protease Inhibitor Cocktail for TBI Protein Workflows
2026-08-16
Learn how an EDTA-free, 100X formulation protects PFKFB3, glycolytic enzymes, and signaling complexes during traumatic brain injury protein workflows. Practical dilution guidance, assay-specific controls, and troubleshooting help preserve samples for Western blotting, co-immunoprecipitation, kinase assays, and related applications.
-
CCCP Workflows for Mitochondrial Assays
2026-08-15
CCCP enables controlled mitochondrial proton gradient disruption for live-cell imaging, bioenergetic stress testing, and orthogonal validation of patient-derived models. This practical guide connects carbonyl cyanide m-chlorophenyl hydrazine with urine-derived stem cell research, AI-based morphology analysis, and reproducible troubleshooting.
-
Esflurbiprofen and SERT–nNOS Fast Antidepressant Action
2026-08-14
The reference study identifies esflurbiprofen as a fast-onset antidepressant candidate by screening for compounds that disrupt the SERT–nNOS complex in the dorsal raphe nucleus. Its combined molecular, behavioral, and rs-fMRI evidence supports a mechanism in which altered serotonin transporter localization reduces autoreceptor-mediated inhibition and restores serotonergic signaling.